Investor Relations

Despite increasing R&D investment, the pharmaceutical industry’s pipeline is producing fewer drugs per year. For each successfully marketed drug, the industry spends hundreds of millions of dollars in R&D. And a larger percentage of this expense can be attributed to costs associated with compounds that ultimately fail.

Clearly, the two conventional methods for filling pharma’s pipeline—advancing internally developed candidates and in-licensing externally-developed ones—are no longer sufficient.

A third way to enrich the industry’s pipeline
Drug repositioning offers pharmaceutical companies a third way to expand their drug development pipelines and is also the primary process through which we are building our own pipeline.

We use our Indication-Seeking Program to evaluate late-stage compounds against hundreds of potential new disease indications. Our efforts are already having an impact. To date, Ore Pharmaceuticals has initiated evaluation of more than 100 compounds provided by our pharmaceutical company partners, with proposed alternative indications for approximately one third of the compounds for which the full evaluations have been completed. And we are now ready to out-license the first repositioned compound from our own pipeline: GL1001.

Producing income
Ore Pharmaceuticals’ business model is based on extracting economic value from dead drugs. Our goal is to produce income in two ways: by monetizing compounds such as GL1001 from our own Drug Development Pipeline through out-licensing or various forms of collaboration; and by earning milestones and royalties from our drug repositioning partners who put their compounds back into their own development pipelines for uses we have identified.